PrintBio occupies a unique position at the intersection of additive manufacturing and regenerative medicine, focusing on 3D-bioprinted living implants and resorbable surgical meshes that are designed to repair or replace damaged human tissues. Unlike permanent synthetic implants, PrintBio's products are engineered to degrade naturally as the body regenerates healthy tissue, reducing long-term complications and revision surgeries.
The company's core technology is built around a proprietary end-to-end biofabrication pipeline that includes GMPrint™ and Uniflex™ platforms. These systems use material extrusion (MEX) bioprinting to fabricate living constructs and resorbable meshes with controlled degradation profiles. PrintBio's lead product, 3DMatrix™, received FDA 510(k) clearance in 2022, marking a milestone as the first FDA-authorized clinical implantation of a 3D-bioprinted living implant.
PrintBio targets surgeons, hospitals, and federal health agencies, with a focus on hernia repair and broader tissue reconstruction. The company has secured partnerships with ARPA-H and the Wake Forest Institute for Regenerative Medicine (WFIRM) as federal consortium partners, and its IP portfolio was spun out of Cornell and Columbia Universities. The company is led by CEO Dr. Kevin Slawin, a surgeon-entrepreneur who previously founded Bellicum Pharmaceuticals and led it to a $161 million IPO.
PrintBio's primary competitive advantage lies in its FDA-cleared resorbable meshes that facilitate natural tissue regeneration, differentiating it from competitors like Aspect Biosystems, Cyfuse, and Allevi. With $31.4 million in funding from investors including Rapha Capital Management, Expa, and Aurum Venture Partners, the company is positioned to scale its clinical and commercial footprint. The key open question is how quickly the company can expand its product pipeline beyond hernia repair into broader orthopedic and soft-tissue applications.
Watch PrintBio
Save it to your watch list and return here after authentication.